Victory Capital Management Inc. Buys Shares of 10,640 Cellebrite DI Ltd. (NASDAQ:CLBT)

Victory Capital Management Inc. bought a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 10,640 shares of the company’s stock, valued at approximately $234,000.

Several other institutional investors and hedge funds have also modified their holdings of CLBT. Quarry LP purchased a new position in shares of Cellebrite DI during the 3rd quarter valued at $27,000. Advisors Asset Management Inc. grew its holdings in shares of Cellebrite DI by 130.5% during the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock valued at $52,000 after acquiring an additional 1,742 shares in the last quarter. R Squared Ltd purchased a new position in shares of Cellebrite DI during the 4th quarter valued at $100,000. Steward Partners Investment Advisory LLC grew its holdings in shares of Cellebrite DI by 12.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 13,590 shares of the company’s stock valued at $299,000 after acquiring an additional 1,463 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd grew its holdings in shares of Cellebrite DI by 35.5% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 19,510 shares of the company’s stock valued at $329,000 after acquiring an additional 5,113 shares in the last quarter. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Cellebrite DI Trading Up 1.0 %

Shares of NASDAQ:CLBT opened at $19.23 on Monday. Cellebrite DI Ltd. has a 1 year low of $10.25 and a 1 year high of $26.30. The firm has a fifty day moving average price of $21.12 and a 200 day moving average price of $19.80. The stock has a market capitalization of $4.61 billion, a PE ratio of -13.83, a P/E/G ratio of 4.27 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, sell-side analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a report on Monday, March 10th. JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Finally, Lake Street Capital upped their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $23.43.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.